Abstract Number: 1703 • 2014 ACR/ARHP Annual Meeting
An Association of Anti-PM/Scl Antibody Reactivity with Risk of Malignancy in Scleroderma
Association of anti-PM/Scl antibody with risk of malignancy in scleroderma. C. Bruni¹, A. Lages², H. Patel3, J. Harvey3, V. Ong4, M. Matucci-Cerinic¹, E. Derrett-Smith4, C.P.…Abstract Number: 1704 • 2014 ACR/ARHP Annual Meeting
CXCL4 Promotes Fibrosis By Increasing Expression of Extracellular Matrix Modifying Factors and By Facilitating Epithelial/Endothelial Mesenchymal Transition
Background/Purpose Systemic sclerosis (SSc) is a degenerative disorder, characterized by vascular abnormalities and immunological disturbances followed by excessive fibrosis in multiple organ systems. In a…Abstract Number: 1723 • 2014 ACR/ARHP Annual Meeting
Identification of the Microbiome As a Potential Trigger of Systemic Sclerosis By Metagenomic RNA-Sequencing of Skin Biopsies
Background/Purpose: Systemic sclerosis (SSc) is a rare and poorly understood systemic autoimmune disease that results in skin fibrosis and severe internal organ involvement. There…Abstract Number: 1722 • 2014 ACR/ARHP Annual Meeting
TLR4 and TLR7 Are Required for Gadolinium Based Contrast Agent Induction of Dermal and Pulmonary Fibrosis in an Adenine-Induced Model of Chronic Renal Failure
Background/Purpose : Nephrogenic Systemic Fibrosis (NSF) is a generalized progressive fibrotic disorder that occurs in some patients with renal insufficiency exposed to various gadolinium based…Abstract Number: 1721 • 2014 ACR/ARHP Annual Meeting
Investigating the SCF/c-Kit Pathway in Scleroderma Fibrosis
Background/Purpose: Stem cell factor (SCF) is a potential driving factor in the development of systemic sclerosis (SSc) and a possible therapeutic target. SCF is a…Abstract Number: 1720 • 2014 ACR/ARHP Annual Meeting
GATA6 Deficiency Activates UPR Pathways in Endothelial Cells during the Development of Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe lung complication of systemic sclerosis (SSc), and accounts for a large proportion of SSc-related deaths. As a…Abstract Number: 1719 • 2014 ACR/ARHP Annual Meeting
Periostin May Promote Productin of Extracellular Matrix By Modulating TGF-β Signaling in Human Skin Fibroblasts
Background/Purpose: Systemic sclerosis (SSc) results in significant morbidity and mortality due to organ fibrosis characterized by increased deposition of extracellular matrix (ECM). Periostin is one…Abstract Number: 1718 • 2014 ACR/ARHP Annual Meeting
B Cell Subsets Homeostasis and Functional Properties Are Altered in a Murine Model of Systemic Sclerosis
Background/Purpose Systemic sclerosis (SSc) is a multi-organ fibrotic disease associated with auto-immune abnormalities. Several clinical and experimental observations suggest that B cells are involved in…Abstract Number: 1690 • 2014 ACR/ARHP Annual Meeting
Improvement of Digital Ulcerative Disease in Patients with Systemic Sclerosis Is Associated with Better Functional Prognosis
Background/Purpose Ischemic digital ulcers (DU) represent a major complication of systemic sclerosis (SSc) leading to hand disability. We investigated the impact of controlling the ulcerative…Abstract Number: 1688 • 2014 ACR/ARHP Annual Meeting
Early Detection of Left Ventricular Morphological, Functional Abnormalities and Myocardial Characteristics in Systemic Sclerosis without Cardiac Symptoms Using Cardiac Magnetic Resonance Imaging: A Preliminary Report
Background/Purpose Systemic sclerosis (SSc) is associated with an increased prevalence of cardiac involvement despite often being clinically silent. Cardiac involvement is a major factor in…Abstract Number: 1687 • 2014 ACR/ARHP Annual Meeting
Key Role of Cardiac Biomarkers in the Assessment of Systemic Sclerosis: Contribution of High Sensitivity Cardiac Troponin
Background/Purpose: Microangiopathy is a cardinal feature of systemic sclerosis (SSc), which plays a critical role in the development of primary myocardial involvement and pulmonary hypertension,…Abstract Number: 1686 • 2014 ACR/ARHP Annual Meeting
DUAL Energy Computed Tomography for the Evaluation of Calcinosis in Systemic Sclerosis
Background/Purpose: To better characterize the soft tissue details of systemic sclerosis--related (SSc) calcinosis of the hands using dual-energy computer tomography (DECT). DECT is an imaging…Abstract Number: 1685 • 2014 ACR/ARHP Annual Meeting
Effects of Mycophenolate Mofetil on Pulmonary Lung Function in Interstitial Lung Disease of Systemic Sclerosis
Background/Purpose: Interstitial lung disease remains a primary driver of morbidity and mortality in patients suffering from systemic sclerosis. Cyclophosphamide currently is the treatment with the…Abstract Number: 1684 • 2014 ACR/ARHP Annual Meeting
Treatment of Scleroderma Associated Lung Disease with Mycophenolate Mofetil: A Community-Based Study
Background/Purpose: Interstitial lung disease occurs in over 80% of patients with scleroderma. Cyclophosphamide is the only treatment proven to benefit scleroderma lung disease in a…Abstract Number: 1683 • 2014 ACR/ARHP Annual Meeting
Botulinum Toxin-a for the Treatment of Severe Raynaud Phenomenon
Background/Purpose Raynaud's phenomenon (RP) is characterized by transient episodes of vasoconstriction of the arteries and arterioles of the extremities in response to cold or emotional…
ACR Meeting Abstracts